Accelerating Vector Construction-To-IND: Achieving A 9-Month Timeline Through Integrated Cell Line Development

Cell line development was one of the key foundations in biologics development and represented a defining step that directly influenced development timelines, product quality, and downstream success. From vector construction to the establishment of a stable Master Cell Bank (MCB), early-stage execution required close coordination across multiple critical processes. Because these activities directly affected IND readiness and overall program velocity, seamless execution across the workflow was essential.

In this webinar, Samsung Biologics introduces its integrated, in-house vector construction and cell banking capabilities. By internalizing these core processes within its facilities, Samsung Biologics enables a smooth progression from vector construction through MCB manufacturing — minimizing external handoffs while supporting consistent data management, controlled information handling, and more agile decision-making.

By watching the presentation below, viewers will learn how these end-to-end in-house capabilities were able to support a VC-to-IND timeline of approximately nine months, delivering faster execution and greater program predictability. The session also walks through in-house workflows and highlights how tighter alignment between vector construction and cell banking improved development efficiency, strengthened risk management, and enhanced early-stage program outcomes.